Plavix Lawsuits Allege Drug Led to Fatal HemorrhagingJun 13, 2012 | Parker Waichman LLP
Three new lawsuits have been filed in Supreme Court of New York on behalf of people who suffered cerebral hemorrhaging while taking the blood thinner drug Plavix.
The Plaintiffs in these latest lawsuits are being represented by the national law firm of Parker Waichman LLP, which represents numerous victims of severe bleeding episodes and other injuries blamed on the top-selling drug Plavix (clopidogrel). The firm recently filed 18 lawsuits on behalf of gastrointestinal hemorrhaging sufferers who also blamed the drug for their life-threatening condition.
The lawsuits on behalf of the cerebral hemorrhaging victims allege its makers Bristol-Myers Squibb and Sanofi-Aventis intentionally hid known side effects of the drug and marketed it as safe and effective at thinning blood to prevent blood clots that could cause heart attacks, stroke, and death.
Being represented by Parker Waichman in these cases include a Hawaiian woman who suffered a cerebral hemorrhage less than a year after starting her Plavix treatment. She was first prescribed the top-selling drug in October 2009 and suffered the life-threatening bleeding episode in June 2010. In another, a Kansas woman claims she developed a cerebral hemorrhage less than two years after starting Plavix. She was prescribed the drug in August 2008 and suffered the serious bleeding episode in June 2010. The third lawsuit is on behalf of a Louisiana woman who suffered a cerebral hemorrhaging episode last summer after first taking Plavix in 2000.
According to a release from the firm announcing the lawsuits, the Plaintiffs all claim they’ve suffered “severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering, loss of enjoyment of life and past, present and future medical expenses.”
The pharmaceutical firms named as Defendants in these and other Plavix injury cases all claim the companies engaged in aggressive marketing campaigns touting their drug as some sort of “super aspirin” meaning it was more effective than the ordinary over-the-counter drug at reducing the risk of blood clots, heart attacks, strokes, and associated death.
This claim has been questioned numerous times by several studies but a 2006 study published in New England Journal of Medicine cast the biggest doubt on it by showing evidence that patients on the combination of Plavix and aspirin showed no greater reduced risk of suffering ischemic events than patients taking aspirin alone.
In addition to the risks of severe hemorrhaging episodes, Plavix has also been blamed for causing Thrombotic Thrombocytopenic Purpura (TTP), ulcers, internal bleeding, and bone marrow damage.